Welcome to our dedicated page for bluebird bio news (Ticker: BLUE), a resource for investors and traders seeking the latest updates and insights on bluebird bio stock.
bluebird bio, Inc. (NASDAQ: BLUE) is a pioneering biotechnology company dedicated to researching, developing, and commercializing gene therapies aimed at treating severe genetic diseases. With a focus on transformative gene therapies, bluebird bio utilizes its proprietary lentiviral vector (LVV) gene addition platform to target a wide range of serious conditions. The company's mission is to develop potentially curative treatments by leveraging its integrated product platforms, which include gene therapy, cancer immunotherapy, and gene editing.
bluebird bio's operations are centered on a single segment dedicated to gene therapy innovation. Recent achievements highlight the company's commitment to advancing healthcare solutions. For instance, bluebird bio has formed strategic partnerships and collaborations aimed at accelerating the development of its gene therapies. These alliances provide critical support in bringing groundbreaking treatments to market.
Current projects at bluebird bio include clinical trials and research focused on severe genetic diseases. The company is exploring potential cures for conditions such as sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. Financially, bluebird bio has demonstrated robust growth and resilience, underpinned by strategic investments and a strong pipeline of products poised for commercialization.
The company's products are designed to address unmet medical needs, offering hope to patients who suffer from debilitating genetic disorders. bluebird bio's dedication extends beyond product development to include patient advocacy and health equity initiatives, ensuring broader access to innovative therapies.
In a recent notable event, Dr. Charlotte Jones-Burton was appointed to bluebird bio's board of directors, bringing a wealth of experience in clinical development and health equity advocacy. This addition signifies the company's ongoing commitment to enhancing its leadership team with experts who can drive strategic growth and innovation.
bluebird bio reported Q3 2021 results, revealing total revenues of $22.7 million, up from $19.3 million in Q3 2020, driven by collaborative arrangements. However, total revenues for the nine months declined to $42.9 million from $240.0 million, influenced by a revenue adjustment related to a previous contract modification. The company completed its separation from 2seventy bio and has a strong cash position of approximately $518.5 million. A net loss of $216.8 million was reported for Q3, reflecting ongoing financial challenges and restructuring costs.
bluebird bio (NASDAQ: BLUE) has signed a long-term lease for a new headquarters in Somerville, Massachusetts, expanding into a 61,000 square foot biotech hub at Assembly Row. This move involves relocating approximately 425 employees in spring 2022 and is anticipated to yield over $120 million in cost savings over six years. The new facility supports a hybrid work model and provides employees with modern amenities. The company will keep its laboratory at
bluebird bio (Nasdaq: BLUE) announced new findings for its gene therapies, betibeglogene autotemcel (beti-cel) and LentiGlobin, to be presented at the American Society of Hematology (ASH) Annual Meeting from December 11-14, 2021. The results indicate long-term efficacy, including sustained iron level stabilization in beta-thalassemia patients and improved quality of life in sickle cell disease patients. A biologics license application for beti-cel has been submitted to the FDA, reinforcing BLUE's commitment to innovative gene therapies.
bluebird bio completed the tax-free spin-off of its oncology programs into 2seventy bio, focusing on gene therapies for severe genetic diseases. The company has three near-term programs targeting sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. It plans to host a spotlight investor call on November 18, 2021, regarding its bb1111 candidate for sickle cell disease. bluebird bio has submitted a biologics licensing application for betibeglogene autotemcel and anticipates a BLA for elivaldogene autotemcel by the end of 2021.
bluebird bio, Inc. (NASDAQ: BLUE) announced that October 19, 2021, will be the record date for the dividend distribution of 2seventy bio, Inc. shares to bluebird stockholders, marking the separation of the two companies. Each stockholder will receive one share of 2seventy for every three shares of bluebird held. The distribution will occur on or about November 4, 2021. The SEC has declared 2seventy’s Registration Statement effective, detailing the tax-free spin-off of bluebird's oncology programs. Expected trading for 2seventy will begin on October 18, 2021, under the symbol 'TSVT'.
bluebird bio has announced a tax-free spin-off of its oncology programs into 2seventy bio, with a completion timeline of early November 2021. Shareholders will receive 1 share of 2seventy bio for every 3 shares of bluebird bio owned. The company expects approximately
bluebird bio has completed a rolling submission of its Biologics License Application (BLA) to the FDA for betibeglogene autotemcel (beti-cel) gene therapy targeting transfusion-dependent β-thalassemia (TDT). This therapy, if approved, will be the first of its kind in the U.S. for TDT patients. The BLA is supported by data from Phase 1/2 and Phase 3 studies, covering over 220 patient-years. Notably, 89% of evaluable patients achieved transfusion independence. The submission reflects bluebird bio's commitment to advancing gene therapies for severe genetic diseases.
2seventy bio, the upcoming oncology spin-off from bluebird bio (NASDAQ: BLUE), has announced a series of investor events to discuss its research pipeline and strategic direction. The first session, scheduled for September 21, 2021, will focus on AML [DARIC33] and their next-gen multiple myeloma strategy. The second session will take place on September 22, 2021, highlighting bNHL [bbT369] and solid tumor strategies. Investors can access live webcasts and recordings for 90 days post-event via the bluebird bio website.
bluebird bio announced a $75 million private placement of common stock and equivalents to fund ongoing R&D and commercialization efforts for itself and upcoming independent company 2seventy bio. The separation is scheduled for October 2021, with an additional $900 million cash expected at that time. Completion of the placement hinges on customary conditions, with closing anticipated in September 2021.
bluebird bio announces key appointments and upcoming investor events ahead of its planned separation, targeted for mid-October 2021.
FAQ
What is the current stock price of bluebird bio (BLUE)?
What is the market cap of bluebird bio (BLUE)?
What is bluebird bio, Inc.?
What does bluebird bio specialize in?
What recent achievements has bluebird bio accomplished?
What are some of bluebird bio's current projects?
What is bluebird bio's financial condition?
What products does bluebird bio offer?
Who are bluebird bio's key partners?
How does bluebird bio ensure health equity?
Who is Dr. Charlotte Jones-Burton?
What is the significance of bluebird bio's gene therapy platform?
